Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients

Irina Raiko1, Ingrid Sander1, Daniel G Weber1, Monika Raulf-Heimsoth1, Adrian Gillissen2, Jens Kollmeier3, Arnaud Scherpereel4, Thomas Brüning1 and Georg Johnen*1

Abstract

Background: Calretinin is one of the well-established immunohistochemical markers in the diagnostics of malignant mesothelioma (MM). Its utility as a diagnostic tool in human blood, however, is scarcely investigated. The aim of this study was to develop an enzyme-linked immunosorbent assay (ELISA) for human calretinin in blood and to assess its usefulness as a potential minimally invasive diagnostic marker for MM.

Methods: Initially, attempts were made to establish an assay using commercially available antibodies and to optimize it by including a biotin-streptavidin complex into the assay protocol. Subsequently, a novel ELISA based on polyclonal antibodies raised in rabbit immunized with human recombinant calretinin was developed. The assay performance in human serum and plasma (EDTA/heparin) and the influence of calcium concentrations on antibody recognition were studied. Stability of spiked-in calretinin in EDTA plasma under different storage conditions was also examined. In preliminary studies serum and plasma samples from 97 healthy volunteers, 35 asbestos-exposed workers, and 42 MM patients were analyzed.

Results: The mean detection range of the new ELISA was 0.12 to 8.97 ng/ml calretinin. The assay demonstrated markedly lower background and significantly higher sensitivity compared to the initially contrived assay that used commercial antibodies. Recovery rate experiments confirmed dependence of calretinin antibody recognition on calcium concentration. Calcium adjustment is necessary for calretinin measurement in EDTA plasma. Spiked-in calretinin revealed high stability in EDTA plasma when stored at room temperature, 4°C, or after repeated freeze/thaw cycles. Median calretinin values in healthy volunteers, asbestos workers, and MM patients were 0.20, 0.33, and 0.84 ng/ml, respectively (p < 0.0001 for healthy vs. MM, p = 0.0036 for healthy vs. asbestos-exposed, p < 0.0001 for asbestos-exposed vs. MM). Median values in patients with epithelioid and biphasic MM were similar. No influence of age, gender, smoking status, or type of medium (plasma/serum) on calretinin values was found.

Conclusions: The novel assay is highly sensitive and applicable to human serum and plasma. Calretinin appears to be a promising marker for the blood-based detection of MM and might complement other markers. However, further studies are required to prove its usefulness in the diagnosis of MM patients.

Background

Malignant mesothelioma (MM) is a highly aggressive tumor of the serous membranes. MM is associated with asbestos exposure and will remain a major health problem on a worldwide scale for many decades [1,2]. Diagnosis of MM usually occurs at late stages of the disease when treatment is very difficult. There is an urgent need for markers for early diagnosis that may improve treatment options. To limit invasive diagnostic procedures, blood-based markers would be preferable. Up to now, sol-
uble mesothelin-related peptides (SMRP) remains, despite of its low sensitivity, the best available serum marker for MM [3-5]. A marker with similar potential is the related N-ERC/mesothelin [6]. While a single tumor marker might not reach sufficient sensitivity and specificity, there is evidence that a panel of several markers could substantially improve diagnosis of cancer [7]. Moreover, reliable and non-invasive tools such as blood markers for screening of high-risk, asbestos-exposed populations are still needed.

Based on immunohistochemical results, such a potential candidate marker might be calretinin. Calretinin (calbindin 2, CALB2) is a 29 kDa calcium-binding protein, a member of the so-called EF-hand protein family frequently found in neurons [8]. It was suggested that calretinin plays a role in intracellular Ca$^{2+}$ homeostasis and buffering [9]. It was shown that calretinin down-regulation blocks the cell cycle and increases apoptosis in the colon adenocarcinoma cell line WiDr [10]. Recently, Henzi et al. presented evidence that calretinin plays a role in cell survival during asbestos exposure. However, its exact role in neoplasia remains unknown [11]. The presence of calretinin was also demonstrated in several other organs and tissues, among them in mesothelium [12]. Since the first evaluation of calretinin as an immunohistochemical marker of MM [13], several studies have demonstrated the significance of calretinin as a reliable marker for the diagnosis of MM, based on its high sensitivity (up to 100%) and specificity (up to 87.5%) in tumor tissues [14-17].

The relevance of calretinin as a potential blood marker for minimally invasive diagnostics of MM has not yet been investigated. Schwaller et al. described calretinin detection in human serum from cancer patients (e.g., ovarian, breast, lung), using a sandwich ELISA [18,19]. However, no sera from patients with MM were analyzed in this study and, to our best knowledge, no further attempts to determine calretinin in serum or plasma were undertaken.

Thus, the purpose of this study was to develop and optimize a novel polyclonal antibody-based ELISA for human calretinin, to test its application in human serum and plasma, and to perform a first assessment of its potential usefulness as a blood test for the diagnostic of MM.

Methods

Human serum and plasma samples

Serum (n = 65) or EDTA plasma samples (n = 32) were collected from 97 healthy volunteers including 54 men (mean age 45 years; range 25-76 years) and 43 women (mean age 41 years; range 25-74 years), and stored at -80°C until use. In addition to serum samples five volunteers also provided EDTA and heparin plasma samples. The 97 volunteers were recruited from employees and former employees of the IPA and the associated clinic and, based on routine occupational-medical examinations, were determined to be apparently healthy. Plasma (n = 10) and serum (n = 25) samples of one female and 34 male workers formerly exposed to asbestos and without evidence of neoplasia (mean age 69, range 55-83 years) were obtained at the IPA and the participating clinics and study centers. The asbestos-exposed group comprised persons without and with benign diseases like pleural plaques or asbestosis, representative of a group of high-risk subjects. Serum and plasma samples (n = 27 and 15, respectively) from 31 men and 11 women with MM (mean age 67 years, range 35-85 years) were analyzed as well. Samples of MM patients were either purchased from conbio (Kiel, Germany) or obtained from the French and German clinics and study centers associated with the study. Histology was known for 32 of the MM cases, with 19 epithelioid, 1 sarcomatoid, and 12 biphasic tumors. Blood samples of MM patients were collected before any anti-tumor treatment. All participants provided written informed consent and permission for the study was obtained from the ethics committee of the Ruhr-University Bochum (reference number 3217-08) or of the Hospital of the University of Lille II, France.

Preparation of anti-calretinin antibodies

For the immunization of a rabbit 0.4 mg human recombinant calretinin (Swant, Belinzona, Switzerland) in TiterMax™ Gold as an adjuvant was injected. In intervals of five to six weeks, the rabbit was boostered twice with 0.4 mg calretinin emulsified with TiterMax™ Gold and was bled four weeks after each boost to check the titer by analysis of the serum. Four months after primary immunization the final antiserum was obtained.

The rabbit serum containing polyclonal anti-calretinin antibodies was loaded via FPLC (Pharmacia, Uppsala, Sweden) on a protein G column (GE Healthcare, Munich, Germany), washed with phosphate-buffer (20 mM, pH 7) and eluted with glycine-HCl-buffer (pH 2.8). Eluted fractions were neutralized directly with 1/10 volume 1 M Tris-HCl-buffer (pH 9), pooled and dialyzed. Protein concentration determined by BSA protein assay (Bio-Rad Laboratories GmbH, Munich, Germany) was 0.9 mg/ml. Aliquots of the purified antibodies were stored at -80°C.

The purified polyclonal anti-calretinin antibodies were biotinylated by mixing with a 33-fold molar excess of biotin-N-hydroxysuccinimid-ester (Roche Diagnostics GmbH, Mannheim, Germany) dissolved in dimethylsulfoxid and incubated under continuous agitation for 4 h at room temperature (RT). The biotinylated antibodies were dialyzed extensively and stored in aliquots at -80°C.
Development of a two-site polyclonal antibody-based ELISA

Assay variant 1 was based on the calretinin sandwich ELISA described previously by Schierle et al. with several modifications [18]. Microtiter plates (MaxiSorp, Nunc, Denmark) were coated with goat polyclonal antibodies to calretinin (CG1; Swant, Belinzona, Switzerland) diluted 1:200 in 0.1 M carbonate/bicarbonate buffer, pH 9.6 (0.5 μg/well), and incubated overnight at 4°C. The plates were blocked with 1.5% (w/v) casein in PBS (200 μl/well) for 120 min at RT (all incubations at RT were carried out under shaking) and then washed three times with PBST (PBS containing 0.05% Tween 20). Human purified recombinant calretinin (Swant) was used as standard. A stock solution (200 μg/ml) was serially diluted in PBST to give calretinin amounts from 2000 to 0.061 ng/ml. After 90 min incubation at RT followed by washing, rabbit polyclonal antibodies to calretinin (7699/4; Swant), diluted 1:1000 with PBST (0.1 μg/well), were added and plates were incubated for another 90 min. Then, goat anti-rabbit IgG peroxidase conjugate (Sigma, Saint Louis, MO, USA), diluted 1:10000 in PBST, was added to the background value of each plate. After washing the plates were incubated for 90 min incubation and washing 100 μl/well of Enhanced K-Blue TMB Substrate (Neogen Corporation, Lexington, KY, USA) was added. The color development was stopped by the addition of 100 μl 0.1 M sulphuric acid per well and absorbance was measured at 414 nm using an automated plate reader (Molecular Devices, Sunnyvale, CA, USA).

In order to improve the assay’s sensitivity, other modifications were applied. In assay variant 2 rabbit polyclonal antibodies to calretinin were used as capture antibody (dilution 1:300 in carbonate/bicarbonate buffer, pH 9.6). The plates were incubated overnight at 4°C, blocked for 120 min at RT and washed three times. Serially diluted calretinin standard (concentrations from 50 to 0.391 ng/ml) was added and plates were incubated overnight at 4°C. After washing the plates were incubated for 90 min with 1:1000 diluted goat polyclonal antibodies and washed again. 60 min after addition of 1:20000 diluted rabbit anti-goat IgG-biotin conjugate (Sigma, Saint Louis, MO, USA) the plates were washed three times and incubated for another 60 min with horseradish-peroxidase-streptavidin conjugate (dilution 1:20000, Fitzgerald Industries International, Concord, MA, USA). After final washing 100 μl/well of ABTS substrate solution (2,2'-azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid), Sigma, Taufkirchen, Germany) were added. The substrate was activated with H₂O₂ according to the manufacturer’s instructions. The enzyme reaction was stopped with 100 μl/well 0.32% NaF and absorbance was measured at 414 nm.

Novel sandwich ELISA using self-developed polyclonal antibodies to calretinin

Assay variant 3 was generated with self-developed purified and biotinylated rabbit polyclonal antibodies to human recombinant calretinin. Microtiter plates were coated with purified polyclonal antibodies (100 μl/well, dilution 1:1500; 0.6 μg/ml; 100 mM carbonate/bicarbonate buffer, pH 9.6) and allowed to adhere overnight at 4°C. They were then blocked with 1.5% casein, washed and incubated with dilutions of the standard and samples for 1 h at RT. A stock solution of human purified recombinant calretinin was diluted in PBST to give standard concentrations between 10 and 0.08 ng/ml. Next, plates were washed three times and incubated for 1 h with biotinylated polyclonal antibodies to calretinin (100 μl/well, dilution 1:5000; 0.18 μg/ml). After washing 100 μl/well of 1:20000 diluted horseradish-peroxidase-streptavidin conjugate (Fitzgerald Industries International, Concord, MA, USA) was added. One hour later plates were washed and 100 μl with H₂O₂-activated ABTS substrate solution was added to each well. The enzyme reaction was stopped by addition of 100 μl 0.32% NaF and absorbance was read at 414 nm.

The dose-response curves for standards were obtained by 4-parameter curve fitting using SoftMax Pro 4.7.1 from Molecular Devices. The lower detection limit of the assay was defined by adding 0.1 OD units (rounded 8-fold mean of the standard deviation of background values from eight plates) to the background value of each plate. Calretinin amounts above that value were considered detectable.

Calretinin recovery rate experiments

Calretinin recovery rates were studied in serum, EDTA plasma, and heparin plasma from healthy individuals. Calretinin concentrations in all these samples were below the detection limit and were called calretinin-negative. In these experiments recovery rates were examined in the presence of various calcium concentrations from 2.5 to 10 mM in dilution buffer (TBST: Tris-buffered saline, pH 7.4 containing 0.05% Tween 20). In addition, the influence of various added calretinin concentrations on its recovery rate in plasma or serum was also studied. Prior to addition of calcium to EDTA plasma, heparin was added to a final concentration of 25 U/ml to avoid potential coagulation after calcium adjustment.

Stability of spiked-in calretinin was studied in EDTA plasma samples from five healthy calretinin-negative individuals. Calretinin (5 ng/ml final concentration) and heparin (25 U/ml plasma) were spiked into each plasma aliquot. Aliquots were handled in four different ways: 5 days at RT, 5 days at 4°C, 5 days at -80°C and 10 freeze/thaw cycles within 5 days. Afterwards, they were diluted.
1:5 with 5 mM CaCl$_2$ in dilution buffer (TBST) and the calretinin recovery rate was measured.

**Statistical analysis**
Nonparametric Mann Whitney’s U test and Kruskal-Wallis test for data comparison were performed with GraphPad Prism (GraphPad Software Inc., San Diego, CA USA). P < 0.05 was considered statistically significant. Pearson’s correlation coefficient was calculated with SAS (SAS Institute Inc., Cary, North Carolina, USA, Version 9.2) to determine the correlation between age and calretinin values. The graphs were created with GraphPad Prism and SigmaPlot 8 (Systat Software Inc., San Jose, CA, USA). Values below standard range of the assay were set to a fixed value based on the four-parameter fit of the standard curve of each run.

**Results**
Initially, we have used commercially available antibodies to establish a new calretinin assay. This assay was based on the only published calretinin ELISA, which was developed by Schierle et al. [19]. Goat anti-calretinin was used as capture antibody and rabbit anti-calretinin as detection antibody. This assay had a high background and a lower detection limit of 5.41 ng/ml (Fig. 1, variant 1). All attempts to improve its sensitivity and to reduce the background failed. An inversion of capture and detection antibodies (rabbit antibodies for capturing and goat antibodies for detection) had no significant effect either (data not shown). Furthermore, a biotin-streptavidin complex amplification by a biotinylated. 

Modification of variant 1 with inversion of capture and detection antibodies and amplification by a streptavidin-biotin complex. Assay variant 1: Capture and detection antibodies based on Schierle et al. [18]. Assay variant 2: Sandwich ELISA with novel polyclonal anti-calretinin rabbit IgG antibody for capturing and detection.
In order to examine the influence of different media on calretinin antibody recognition, recovery rates were studied in calretinin-negative sera and plasma samples (EDTA and heparin) from the same healthy individuals. Samples were diluted 1:5 either with TBST or with 5 mM CaCl$_2$ in TBST and 5 ng/ml calretinin was spiked-in to each sample. The resulting recovery rates are shown in Fig. 2C. They were 89.9 ± 12.9% and 92.2 ± 15.7% (n = 11) in serum and heparin plasma, respectively. Similar results were obtained with lower added calretinin concentrations (0.625, 1.25, and 2.5 ng/ml). Calcium addition revealed no influence on the antibody recognition of calretinin in serum and heparin plasma (data not shown). Like in the experiments with EDTA plasma dilutions, recovery rates in EDTA plasma samples without calcium addition were low (21.3 ± 5.0%). In EDTA plasma resupplied with calcium, however, they were comparable with those in serum and heparin plasma (96.1 ± 15.5%).

Spiked-in calretinin revealed a high stability when stored for 5 days at -80°C, 4°C, or even RT. Likewise, up to 10 freeze/thaw cycles had no significant influence on its recovery rate. The measured values of calretinin were from 4.9 to 5.1 ng/ml and its recovery rates were about 100% (data not shown).

In a preliminary assessment of calretinin as a possible tumor marker its concentrations were measured in 1:2 to 1:4 diluted sera from healthy subjects (n = 65) and from patients with diagnosed MM (n = 27) as well as in 1:5 diluted EDTA plasmas (32 healthy subjects and 15 patients with MM). As shown in Fig. 3, the median values of calretinin in serum and plasma of MM patients were significantly higher than in blood samples from healthy controls (0.84 vs. 0.20 ng/ml; p < 0.0001) or from asbestos-exposed workers (0.84 vs. 0.33 ng/ml; p < 0.0001). There was also a significant difference between calretinin blood levels in asbestos-exposed workers versus healthy controls (0.33 vs. 0.20 ng/ml, respectively; p = 0.0036). Regarding the histological MM subtype, patients with epithelioid MM did not exhibit significantly different median serum levels of calretinin than patients with biphasic MM (0.87 vs. 0.90 ng/ml, respectively; p = 0.41) (Fig. 4). Because we had only one sarcomatoid MM in our collective, a meaningful statistical analysis for this subtype was not possible. Median calretinin values in serum vs. plasma revealed no significant differences within the group of healthy controls (0.19 vs. 0.21 ng/ml, respectively; p = 0.69), asbestos-exposed workers (0.31 vs. 0.42 ng/ml, respectively; p = 0.55), or MM patients (0.77 vs. 1.02 ng/ml, respectively; p = 0.96). There was no significant difference in the median blood calretinin value in the healthy subjects group, depending on their age (Pearson’s correlation coefficient, r = -0.11; p = 0.27), their sex (men vs. women: 0.21 vs. 0.20 ng/ml; p = 0.56), or their smoking status (smokers (n = 11), ex-smokers (n = 11), and non-smokers (n = 45): 0.23, 0.23, and 0.21 ng/ml respectively; p = 0.83).

**Discussion**

Calretinin is one of the best and most frequently used markers in the immunohistochemical diagnosis of MM [17,23]. Its value as a blood-based tumor marker in MM
remains to be proven. A minimally invasive blood marker would greatly improve diagnosis and early detection of MM. Schwaller et al. detected calretinin and its splice form calretinin-22k in sera from patients with tumors of various localizations as well as from healthy persons [19]. Although the calretinin values in the patient group were considerably higher than in the control group, the relatively low number of samples in each category did not allow for an association with the pathological condition. To our knowledge, no other studies to assess soluble calretinin in human blood have been performed yet.

To develop a novel sandwich ELISA, we have used polyclonal antibodies raised in rabbit after injection of human recombinant calretinin. Compared to assay variants 1 and 2 with commercial antibodies, the novel assay is reproducible, provides higher sensitivity (about 46 and 4 times higher than those of variants 1 and 2, respectively), has noticeably lower background, and exhibits a steeply rising calibration curve. In the assay variants 1 and 2 capture and detection antibodies are polyclonal and were raised in different species (rabbit and goat, respectively). To facilitate a final enzyme reaction in these assay variants, a labeled secondary antibody against the detection antibody was used (e.g., goat anti-rabbit IgG peroxidase conjugate in variant 1). Although this secondary antibody was raised in the same species as the capture one (goat in variant 1), it revealed some non-specific binding to the latter (data not shown). The high background observed in the assay variants 1 and 2 was partially caused by this non-specific binding. In the novel ELISA we have used biotinylated anti-calretinin as a detection antibody, thereby a labeled secondary detection antibody was dis-

![Figure 3](image3.png)

**Figure 3 Calretinin levels in blood samples.** Individual values for calretinin in healthy subjects (n = 97), persons with previous asbestos exposure (n = 35), and patients with malignant mesothelioma (n = 42). Open circles represent serum, filled circles plasma samples. Bars indicate median marker levels. Differences between all groups were significant (p < 0.0001 for healthy vs. MM, p = 0.0036 for healthy vs. asbestos-exposed, p < 0.0001 for asbestos-exposed vs. MM).

![Figure 4](image4.png)

**Figure 4 Calretinin levels and histological subtypes.** Values of calretinin in blood samples of patients with epithelioid (n = 19) and biphasic MM (n = 12). Bars indicate median marker levels. The difference between the two subtypes was not significant (p = 0.41).
The background of this assay variant is significantly lower, supporting our explanation of the high background in assay variants 1 and 2. Furthermore, the novel assay has fewer steps and requires less time. In addition, considerably lower concentrations of capture and detection antibodies are required for its performance (0.6 μg/ml and 0.18 μg/ml compared to 5 μg/ml and 1 μg/ml for variant 1, respectively) and therefore it is less expensive.

The choice of appropriate sample type (serum or plasma) and anticoagulant (EDTA, heparin, or citrate) is of great importance for the practical use of assays. Until now calretinin concentration in human blood was determined only in serum samples [19]. In the present study we investigated for the first time calretinin values in EDTA and heparin plasma as well as in serum, using recovery rate experiments.

In our initial studies we have observed very low recovery rates of spiked-in calretinin in EDTA plasma (15-20%). They were clearly improved after addition of CaCl₂ to the dilution buffer. Similar effects were described for the ELISA-based detection of S100A12 in EDTA plasma, another Ca²⁺-binding protein of the EF-hand family [24]. It is known that calretinin antibody recognition depends on its Ca²⁺-binding status and it was experimentally confirmed that Ca²⁺ induces conformational changes in the calretinin molecule that likely promote antibody recognition [20-22]. These findings explain the initially low recovery rates observed in our experiments, because EDTA strongly binds calcium so that the remaining concentration in plasma is not sufficient to provide appropriate conformational changes necessary for optimal antibody recognition. Subsequently, we found a Ca²⁺ concentration in the dilution buffer of 5 mM in combination with a plasma dilution of 1:5 to be optimal. Also, due to the lower viscosity of diluted plasma antibody recognition is less impeded and assay reproducibility is thus improved.

Despite rules for proper tissue banking, in reality samples might not always be handled according to standard operating procedures, leading to altered marker levels [25]. Our present study indicates that calretinin concentration in plasma is not altered after repeated freeze/thaw cycles or during the storage at RT or 4°C for at least five days. These results suggest that calretinin might be a stable marker applicable in field studies.

Using our sandwich ELISA, we determined calretinin levels in serum and EDTA plasma from patients with MM, asbestos-exposed persons (with and without benign lung or pleural diseases), and healthy controls. Significantly higher values were observed in MM samples compared to samples of healthy volunteers or asbestos-exposed persons without malignancies. This result - after confirmation in a larger group of patients - may suggest blood calretinin as a soluble marker for the (early) diagnosis of MM.

Current MM markers such as soluble mesothelin (SMRP) mainly detect epithelioid MM, while biphasic and especially sarcomatoid MM are frequently missed. Based on immunohistochemistry, calretinin is known to be detected in epithelioid MM but can also be found in other MM subtypes [13,17]. Our results indicate that this finding - at least for epithelial and biphasic MM - could be extended to the detection of this marker in blood samples.

On the basis of our initial results we suggest that the measurement of calretinin in human serum and plasma might be a useful marker for the diagnosis of MM, alone or combined with other markers such as soluble mesothelin. However, these results are based on relatively small numbers and further studies on more patients, including subgroups of subjects with other tumors and non-malignant lung or pleural diseases, are needed to confirm our initial data. Such a study is presently ongoing. In addition, to validate a new marker for early detection of cancer the most suitable design is that of a prospective study. Currently, we are establishing a large cohort of patients with benign asbestos-related diseases to evaluate calretinin and other potential markers within a longitudinal study.

Conclusions
We have developed a novel and sensitive ELISA for the detection of calretinin in serum, heparin plasma, or EDTA plasma augmented with calcium. No significant differences between calretinin recovery rates in serum or plasma were detected. Also, high calretinin stability was observed under several storage conditions as well as after repeated freeze/thaw cycles. Calretinin levels were significantly increased in MM patients, suggesting that it might be suitable - possibly in combination with other markers like mesothelin - for the blood-based detection of MM. These factors provide a promising basis for the validation of calretinin as a biomarker for MM in larger case-control as well as prospective studies.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
IR carried out the immunoassays, performed the statistical analysis, and drafted the manuscript. IS participated in the design of the assays and helped to draft the manuscript. DGW participated in the design and coordination of the study and helped to draft the manuscript. MBH helped with the assay design and the draft of the manuscript. JK participated in the coordination of the study and helped with the draft. AG participated in the coordination of the study and helped with the draft of the manuscript. AS participated in study design and patient recruitment and helped to draft the manuscript. TB participated in the study design and coordination. GJ conceived of the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank E. Zährndruck and U. Meurer for skilled technical support. We are grateful to Dr. J. Henry, Prof. Dr. R. Mierget (IPA), Dr. M. Imoîl (University Clinic Bergmannsheil, Bochum), Prof. Dr. T. Bauer (HELIOS Clinic Emil von Behring, Respiratory Diseases Clinic Heckeshorn, Berlin, Germany), and Dr. C. Sellek-Seehafer (Bremen, Germany) for providing plasma samples. We are grateful to S. Cajsins for supporting the statistical analysis.

Author Details
1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance of the Ruhr-University Bochum (IPA), Büdike–de-Camp-Platz 1, 44789 Bochum, Germany, 2George Medical Centre, Robert-Koch-Hospital, Nikolai-Rumanjawn-Strasse 100, 04207 Leipzig, Germany, 3HELIOS Clinic Emil von Behring, Respiratory Diseases Clinic Heckeshorn, Walterhoferstrasse 11, 14165 Berlin, Germany and 5Service de Pneumologie et d’Oncologie Thoracique, Hôpital Calmette - Hospital of the University of Lille II, 59037 Lille, France.

Received: 6 November 2009 Accepted: 28 May 2010
Published: 28 May 2010

References
1. Greilier L, Baas P, Welch JJ, Hasan B, Passioukov A: Biomarkers for malignant pleural mesotheloma: current status. Mol Diagn Ther 2008, 12(6):375-390.
2. Scherpeereel A, Lee YG: Biomarkers for mesothelioma. Curr Opin Pulm Med 2007, 13(4):339-443.
3. Creaney J, Robinson BW: Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 2009, 15(4):366-370.
4. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR: Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008, 178(8):832-837.
5. Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, Kraus T, Bruning T, Gube M: Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum. Biomark Insights 2010, 5:1-8.
6. Shio Mi, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Masuda K, Hira-bayashi M, Moroboshi T, et al.: Sensitive and specific new enzyme-linked immunosorbent assay for N-ER/C-mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 2008, 14(5):1431-1437.
7. Porcal JM, Vives M, Esquerra A, Salud A, Perez B, Rodriguez-Panadero F: Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004, 126(6):1757-1763.
8. Rogers JH: Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons. J Cell Biol 1987, 105(3):1531-1533.
9. Schwallier G, Gander JC, Grottoz V, Felday B, Schwallier B: Inhibition of the proliferative cycle and apoptotic events in WiDr cells after down-regulation of the calcium-binding protein calretinin using antisense oligodeoxynucleotides. Exp Cell Res 1996, 225(2):399-410.
10. Henzi T, Blum WV, Pfefferli M, Kawecki TJ, Salicio V, Schwallier B: SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am J Pathol 2009, 174(6):2324-2336.
11. Grottoz V, Vogt P, Cellot MR: The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996, 192(2):137-147.
12. Doglioni C, Tos AP, Laurino L, Iuzzolini P, Chiarelli C, Cellot MR, Viale G: Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Pathol 2006, 169(3):1037-1046.
13. King JE, Thatcher N, Pickering CA, Hasleton PS: Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelial mesothelioma: a detailed systematic analysis using published data. Histopathology 2006, 48(3):223-232.
14. Schwallier B, Cellot MR, Doglioni C: Identification of calretinin and the alternatively spliced form calretinin-22k in primary pleural mesotheliomas and in their metastases. Anticancer Res 2004, 24(6):4003-4009.
15. Comin CE, Saieva C, Messerlini L: h-caldesmon, calretinin, estrogen receptor, and Ber-Ep4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007, 31(8):1139-1148.
16. Ordonez NG: What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007, 38(1):1-16.
17. Schiefer GS, Gander JC, D’ Orlando C, Cellot MR, Vogt Weissenhorn DM: Calretinin-immunoreactivity during postnatal development of the rat isocortex: a qualitative and quantitative study. Cereb Cortex 1997, 7(2):130-142.
18. Schwallier B, Meyer-Monard S, Gander JC, Pugin P, Cellot MR, Ludwig C: The calcium-binding protein calretinin-22k is detectable in the serum and specific cells of cancer patients. Anticancer Res 1998, 18(3B):3661-3667.
19. Winsky L, Kuznicki J: Antibody recognition of calcium-binding proteins depends on their calcium-binding status. J Neurochem 1996, 66(2):764-771.
20. Zimmermann L, Schwallier B: Monoclonal antibodies recognizing epitopes of calretinins: dependence on Ca2+-binding status and differences in antigen accessibility in colon cancer cells. Cell Calcium 2002, 31(1):13-25.
21. Schwallier B, Durussel I, Jermann D, Herrmann B, Cox JA: Comparison of the Ca2+-binding properties of human recombinant calretinin-22k and calretinin. J Biol Chem 1997, 272(47):29663-29671.
22. Werthege T: Differential diagnosis of other tumors - Immunohistochemical and molecular biological Untersuchungsverfahren. In PhD Thesis University Essen; 2000.
23. Larsen A, Bronstein IB, Dahl O, Wentzel-Larsen T, Kristoffersen ET, Fagerhol MK: Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin. Scand J Immunol 2007, 65(2):192-201.
24. Weber DG, Taeger D, Pesch B, Kraus T, Bruning T, Johnen G: Soluble mesothelin-related peptides (SMRP) - High stability of a potential tumor marker for mesothelioma. Cancer Biomark 2007, 3(6):287-292.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10242/prepub